The pharma industry in India is entering a very interesting variant of the post-digital marketing era. The term “post-digital marketing” is used to depict a state where the lines between physical and digital blur considerably for a customer. However, in the context of pharma, this means a state where the industry has stopped questioning the need for digital and has begun to implement very interesting digital marketing initiatives.

72nd Republic Day: What’s the Road Ahead for Indian Pharma?

“We are getting too happy, for too little”: these...

Pharma CEO Roundtable – Engaging Doctors – Physical, Digital and Hybrid: Translating Strategy into Action

The MedicinMan 10th Anniversary Special - Pharma CEO Roundtable...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025 India’s pharmaceutical industry, a global powerhouse, sends...

Marketing

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025 India’s pharmaceutical industry, a global powerhouse, sends...

Policies/Sales

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025 India’s pharmaceutical industry, a global powerhouse, sends...

Strategy

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...

How Trump’s Tariff War Could Affect India’s Top 25 Pharma Companies

April 14, 2025 India’s pharmaceutical industry, a global powerhouse, sends...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Finding the middle ground for Doctor-Stakeholder Relationship

Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence

Have Tech Advances Made UCPMP Obsolete? Need for Contemporary Pharma Marketing Code

Salil Kallianpur The code of conduct for ethical pharmaceutical marketing...

MedicinMan Indian Pharma Digital Adoption Survey

Smaller Indian pharma companies bore the strongest impact from...

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."